Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients

Herwig Ulf Meier-Kriesche, Akinlolu O. Ojo, Alan B. Leichtman, Jeffrey D. Punch, Julie A. Hanson, Diane M. Cibrik, Bruce Kaplan

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

African American renal transplant recipients have poorer graft survival. A study using the United States Renal Data Registry documented an improvement in graft survival for patients who took mycophenolate mofetil (MMF) compared with azathioprine (AZA). This analysis did not address the impact of MMF on African American renal transplant recipients. The present study aimed to quantify potential beneficial effects of MMF therapy on long-term renal allograft survival in African Americans. With the use of the United States Renal Data Registry, all adult Caucasian and African American patients who had received a primary renal transplant between 1988 and 1997 were analyzed by Kaplan-Meier analysis and Cox proportional hazard models. Primary study end points were death with a functioning graft and graft failure censored for death. A total of 57,926 patients were studied. For African Americans, 3-yr patient survival was 96.3 versus 93.2% (P <0.001) for MMF and AZA, respectively. Three-yr death-censored graft survival for African Americans was 85.8 versus 75.1% (P <0.001) for MMF and AZA, respectively. For Caucasians, 3-yr patient survival was 97.3 versus 93.2% for MMF and AZA, respectively. Three-yr death-censored graft survival for Caucasians was 90.1 versus 86.4% (P <0.001) for MMF and AZA, respectively. By multivariate analysis, MMF was associated with a significant reduction in the relative risk for all study end points in African Americans. MMF therapy is associated with both improved patient and death-censored graft survival in African American renal transplant recipients. This benefit is comparable to the benefit of MMF in Caucasian renal transplant recipients.

Original languageEnglish (US)
Pages (from-to)2366-2370
Number of pages5
JournalJournal of the American Society of Nephrology
Volume11
Issue number12
StatePublished - 2000
Externally publishedYes

Fingerprint

Mycophenolic Acid
African Americans
Kidney
Azathioprine
Graft Survival
Transplants
Registries
Transplant Recipients
Survival
Kaplan-Meier Estimate
Proportional Hazards Models
Allografts
Multivariate Analysis

ASJC Scopus subject areas

  • Nephrology

Cite this

Meier-Kriesche, H. U., Ojo, A. O., Leichtman, A. B., Punch, J. D., Hanson, J. A., Cibrik, D. M., & Kaplan, B. (2000). Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. Journal of the American Society of Nephrology, 11(12), 2366-2370.

Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. / Meier-Kriesche, Herwig Ulf; Ojo, Akinlolu O.; Leichtman, Alan B.; Punch, Jeffrey D.; Hanson, Julie A.; Cibrik, Diane M.; Kaplan, Bruce.

In: Journal of the American Society of Nephrology, Vol. 11, No. 12, 2000, p. 2366-2370.

Research output: Contribution to journalArticle

Meier-Kriesche, HU, Ojo, AO, Leichtman, AB, Punch, JD, Hanson, JA, Cibrik, DM & Kaplan, B 2000, 'Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients', Journal of the American Society of Nephrology, vol. 11, no. 12, pp. 2366-2370.
Meier-Kriesche HU, Ojo AO, Leichtman AB, Punch JD, Hanson JA, Cibrik DM et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. Journal of the American Society of Nephrology. 2000;11(12):2366-2370.
Meier-Kriesche, Herwig Ulf ; Ojo, Akinlolu O. ; Leichtman, Alan B. ; Punch, Jeffrey D. ; Hanson, Julie A. ; Cibrik, Diane M. ; Kaplan, Bruce. / Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. In: Journal of the American Society of Nephrology. 2000 ; Vol. 11, No. 12. pp. 2366-2370.
@article{21c92b2caba949b9a7a79829d94bf7d0,
title = "Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients",
abstract = "African American renal transplant recipients have poorer graft survival. A study using the United States Renal Data Registry documented an improvement in graft survival for patients who took mycophenolate mofetil (MMF) compared with azathioprine (AZA). This analysis did not address the impact of MMF on African American renal transplant recipients. The present study aimed to quantify potential beneficial effects of MMF therapy on long-term renal allograft survival in African Americans. With the use of the United States Renal Data Registry, all adult Caucasian and African American patients who had received a primary renal transplant between 1988 and 1997 were analyzed by Kaplan-Meier analysis and Cox proportional hazard models. Primary study end points were death with a functioning graft and graft failure censored for death. A total of 57,926 patients were studied. For African Americans, 3-yr patient survival was 96.3 versus 93.2{\%} (P <0.001) for MMF and AZA, respectively. Three-yr death-censored graft survival for African Americans was 85.8 versus 75.1{\%} (P <0.001) for MMF and AZA, respectively. For Caucasians, 3-yr patient survival was 97.3 versus 93.2{\%} for MMF and AZA, respectively. Three-yr death-censored graft survival for Caucasians was 90.1 versus 86.4{\%} (P <0.001) for MMF and AZA, respectively. By multivariate analysis, MMF was associated with a significant reduction in the relative risk for all study end points in African Americans. MMF therapy is associated with both improved patient and death-censored graft survival in African American renal transplant recipients. This benefit is comparable to the benefit of MMF in Caucasian renal transplant recipients.",
author = "Meier-Kriesche, {Herwig Ulf} and Ojo, {Akinlolu O.} and Leichtman, {Alan B.} and Punch, {Jeffrey D.} and Hanson, {Julie A.} and Cibrik, {Diane M.} and Bruce Kaplan",
year = "2000",
language = "English (US)",
volume = "11",
pages = "2366--2370",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "12",

}

TY - JOUR

T1 - Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients

AU - Meier-Kriesche, Herwig Ulf

AU - Ojo, Akinlolu O.

AU - Leichtman, Alan B.

AU - Punch, Jeffrey D.

AU - Hanson, Julie A.

AU - Cibrik, Diane M.

AU - Kaplan, Bruce

PY - 2000

Y1 - 2000

N2 - African American renal transplant recipients have poorer graft survival. A study using the United States Renal Data Registry documented an improvement in graft survival for patients who took mycophenolate mofetil (MMF) compared with azathioprine (AZA). This analysis did not address the impact of MMF on African American renal transplant recipients. The present study aimed to quantify potential beneficial effects of MMF therapy on long-term renal allograft survival in African Americans. With the use of the United States Renal Data Registry, all adult Caucasian and African American patients who had received a primary renal transplant between 1988 and 1997 were analyzed by Kaplan-Meier analysis and Cox proportional hazard models. Primary study end points were death with a functioning graft and graft failure censored for death. A total of 57,926 patients were studied. For African Americans, 3-yr patient survival was 96.3 versus 93.2% (P <0.001) for MMF and AZA, respectively. Three-yr death-censored graft survival for African Americans was 85.8 versus 75.1% (P <0.001) for MMF and AZA, respectively. For Caucasians, 3-yr patient survival was 97.3 versus 93.2% for MMF and AZA, respectively. Three-yr death-censored graft survival for Caucasians was 90.1 versus 86.4% (P <0.001) for MMF and AZA, respectively. By multivariate analysis, MMF was associated with a significant reduction in the relative risk for all study end points in African Americans. MMF therapy is associated with both improved patient and death-censored graft survival in African American renal transplant recipients. This benefit is comparable to the benefit of MMF in Caucasian renal transplant recipients.

AB - African American renal transplant recipients have poorer graft survival. A study using the United States Renal Data Registry documented an improvement in graft survival for patients who took mycophenolate mofetil (MMF) compared with azathioprine (AZA). This analysis did not address the impact of MMF on African American renal transplant recipients. The present study aimed to quantify potential beneficial effects of MMF therapy on long-term renal allograft survival in African Americans. With the use of the United States Renal Data Registry, all adult Caucasian and African American patients who had received a primary renal transplant between 1988 and 1997 were analyzed by Kaplan-Meier analysis and Cox proportional hazard models. Primary study end points were death with a functioning graft and graft failure censored for death. A total of 57,926 patients were studied. For African Americans, 3-yr patient survival was 96.3 versus 93.2% (P <0.001) for MMF and AZA, respectively. Three-yr death-censored graft survival for African Americans was 85.8 versus 75.1% (P <0.001) for MMF and AZA, respectively. For Caucasians, 3-yr patient survival was 97.3 versus 93.2% for MMF and AZA, respectively. Three-yr death-censored graft survival for Caucasians was 90.1 versus 86.4% (P <0.001) for MMF and AZA, respectively. By multivariate analysis, MMF was associated with a significant reduction in the relative risk for all study end points in African Americans. MMF therapy is associated with both improved patient and death-censored graft survival in African American renal transplant recipients. This benefit is comparable to the benefit of MMF in Caucasian renal transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=0033663061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033663061&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 2366

EP - 2370

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 12

ER -